Krystal Biotech, Inc. (KRYS) Misses Q2 EPS by 9c

Go back to Krystal Biotech, Inc. (KRYS) Misses Q2 EPS by 9c

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

August 8, 2022 7:00 AM EDT

Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments

PITTSBURGH, Aug. 08, 2022 (GLOBE NEWSWIRE) --... More